Sugi Predict

Sugi Predict / Targets / IL15RA

IL15RA

Interleukin-15 receptor subunit alpha (IL-15 · Q13261 · IL15RA on Sugi Atlas →

124 patent compounds predicted against IL15RA, 90 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17293539 SCHEMBL17293539 1.00 20/20
SCHEMBL17293788 SCHEMBL17293788 1.00 20/20
SCHEMBL17293831 SCHEMBL17293831 1.00 20/20
SCHEMBL17293839 SCHEMBL17293839 1.00 20/20
SCHEMBL17293612 SCHEMBL17293612 1.00 19/20
SCHEMBL17293792 SCHEMBL17293792 1.00 19/20
SCHEMBL17293797 SCHEMBL17293797 1.00 19/20
SCHEMBL17293815 SCHEMBL17293815 1.00 19/20
SCHEMBL31158149 SCHEMBL31158149 1.00 19/20
SCHEMBL31158150 SCHEMBL31158150 1.00 19/20
SCHEMBL17302311 SCHEMBL17302311 0.86 19/20
SCHEMBL17293856 SCHEMBL17293856 0.82 19/20
SCHEMBL17293749 SCHEMBL17293749 0.74 19/20
SCHEMBL17293791 SCHEMBL17293791 0.74 19/20
SCHEMBL17293880 SCHEMBL17293880 0.68 19/20
SCHEMBL17293829 SCHEMBL17293829 0.63 19/20
SCHEMBL17293542 SCHEMBL17293542 1.00 17/20
SCHEMBL17293576 SCHEMBL17293576 0.82 17/20
SCHEMBL17293591 SCHEMBL17293591 0.70 17/20
SCHEMBL17293745 SCHEMBL17293745 0.70 17/20

Clinical trials — most relevant to IL15RA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC PHASE3WITHDRAWN
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia PHASE3WITHDRAWN
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma PHASE2COMPLETED
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. PHASE2WITHDRAWN
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection PHASE1/PHASE2COMPLETED
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma PHASE2RECRUITING
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma PHASE1/PHASE2COMPLETED
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients PHASE2COMPLETED
Immunotherapy Before and After Surgery PHASE2WITHDRAWN
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia PHASE2RECRUITING
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction PHASE2RECRUITING
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer PHASE1COMPLETED
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer PHASE1COMPLETED
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers PHASE1COMPLETED
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome PHASE1COMPLETED
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies PHASE1COMPLETED
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors PHASE1UNKNOWN
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer PHASE1COMPLETED
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) PHASE1COMPLETED
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors PHASE1COMPLETED
Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID) PHASE1COMPLETED
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 PHASE1RECRUITING
Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK) PHASE1RECRUITING
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) PHASE1COMPLETED
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis PHASE1COMPLETED
Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia PHASE1COMPLETED
IL13Rα2 CAR-T for Patients With r/r Glioma PHASE1SUSPENDED
Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases. nanCOMPLETED
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors nanRECRUITING
Genetic Basis of Immunodeficiency nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a IL15RA binder may also engage these)

ProteinNameSimilarity
Q60819 — 0.992 Q60819 →
Q5T2D2 — 0.980 Q5T2D2 →
A0A1B0GV85 — 0.978 A0A1B0GV85 →
Q8CAE9 — 0.978 Q8CAE9 →
Q6UXG3 — 0.977 Q6UXG3 →
Q2TB54 — 0.976 Q2TB54 →
Q1ERP8 — 0.975 Q1ERP8 →
Q9ET35 — 0.974 Q9ET35 →
Q9D3L0 — 0.973 Q9D3L0 →
Q58D34 — 0.973 Q58D34 →
Q2LA85 — 0.972 Q2LA85 →
Q6UWI2 — 0.972 Q6UWI2 →
Q5R770 — 0.971 Q5R770 →
P09603 — 0.971 P09603 →
Q8WWV6 — 0.971 Q8WWV6 →
P41272 — 0.970 P41272 →
Q6UXB8 — 0.970 Q6UXB8 →
Q64314 — 0.970 Q64314 →
Q8BX43 — 0.970 Q8BX43 →
P22273 — 0.970 P22273 →
O14836 — 0.970 O14836 →
P78423 — 0.970 P78423 →
Q8NBI3 — 0.970 Q8NBI3 →
Q8R138 — 0.969 Q8R138 →
Q6PAL1 — 0.969 Q6PAL1 →
P20333 — 0.969 P20333 →
Q5FVQ7 — 0.969 Q5FVQ7 →
P0C8S2 — 0.969 P0C8S2 →
Q9ET66 — 0.968 Q9ET66 →
P28906 — 0.968 P28906 →